Avelumab is used to treat a type of skin cancer called Merkel cell carcinoma in adults and children at least 12 years old, when the cancer has spread to other parts of the body (metastatic). Avelumab is also used to treat a certain type of cancer of the bladder or urinary tract that has spread or cannot be removed with surgery.

Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. [5]

Avelumab injection is used to treat Merkel cell carcinoma (MCC; a type of skin cancer) that has spread to other parts of the body in adults and children 12 years of age and older.

2017年4月1日 · Avelumab is a type of drug called an immune checkpoint inhibitor. It works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells.

On June 30, 2020, the Food and Drug Administration approved avelumab (BAVENCIO, EMD Serono, Inc.) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma...

Avelumab is used to treat various types of cancer. It works by changing the action of your own immune system, directing it to attack cancer cells. Avelumab belongs to a class of drugs known as...

Avelumab is an anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.

2025年3月1日 · Avelumab injection is used to treat a kind of skin cancer called Merkel cell carcinoma (MCC) that has spread. Avelumab injection is also used to treat urothelial carcinoma (a type of urinary tract cancer), that has spread throughout the body (metastatic) or cannot be removed by surgery (locally advanced).

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth.